Asset Details
Do you wish to reserve the book?
Advanced Human Immune Cell‐Organoid Co‐Cultures for Functional Testing of Cancer Nanovaccines
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Advanced Human Immune Cell‐Organoid Co‐Cultures for Functional Testing of Cancer Nanovaccines
Do you wish to request the book?
Advanced Human Immune Cell‐Organoid Co‐Cultures for Functional Testing of Cancer Nanovaccines
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Advanced Human Immune Cell‐Organoid Co‐Cultures for Functional Testing of Cancer Nanovaccines
2026
Overview
Pancreatic ductal adenocarcinoma (PDAC) remains a major clinical challenge due to late detection and limited treatment responsiveness. To better evaluate complex immunotherapies in a human‐relevant setting, we developed an integrated organoid–immune co‐culture pipeline using PDAC patient‐derived organoids (PDOs) and matched HLA immune cells. As a proof of concept, we assessed an MSLN‐targeted nanovaccine (Mesovac), alone and in combination with FOLFIRINOX chemotherapy and Atezolizumab. We evaluated Mesovac across a multi‐stage pipeline, including T‐cell stimulation, ex vivo expansion, and PDO‐immune co‐cultures, to assess immune activation, specificity, and synergy with combinatorial treatments. MSLN‐stimulated T‐cells, derived from PDAC patients, showed increased IFN‐γ production and selective infiltration into MSLN‐expressing PDOs. Artificial antigen‐presenting cells (aAPCs) boosted the expansion of reactive T‐cells, enhancing antitumor responses. Notably, combining Mesovac with FOLFIRINOX and Atezolizumab maintained PD‐L1+ T‐cell levels and reduced cancer stem cells and aggressive PDAC subsets. Using this advanced in vitro workflow, we highlight that this platform, using human organoid–immune cell co‐cultures, enables the evaluation of complex processes related to nanovaccine strategies that would not be possible in vivo. Pancreatic ductal adenocarcinoma remains difficult to treat. We establish an organoid–immune co‐culture using patient‐derived organoids and matched T‐cells to assess cancer vaccines. A mesothelin‐targeted nanovaccine activates antigen‐specific T‐cells, increases IFN‐γ, and targets MSLN+ organoids. Combined with FOLFIRINOX and Atezolizumab, it reduces stemness and maintains immune activity, enabling personalized ex vivo vaccine evaluation.
Publisher
John Wiley & Sons, Inc,Wiley
Subject
/ Antibodies, Monoclonal, Humanized - pharmacology
/ Antigens
/ Antineoplastic Combined Chemotherapy Protocols - pharmacology
/ Cancer Vaccines - immunology
/ Carcinoma, Pancreatic Ductal - drug therapy
/ Carcinoma, Pancreatic Ductal - immunology
/ Carcinoma, Pancreatic Ductal - therapy
/ Coculture Techniques - methods
/ Ethanol
/ Humans
/ Pancreatic Neoplasms - drug therapy
/ Pancreatic Neoplasms - immunology
/ Pancreatic Neoplasms - therapy
/ Patients
/ PDAC
